""

Renal cell carcinoma

Recruiting after consultation
Open recruiting

Neoadjuvant Therapy

There are currently no studies available

Adjuvant Therapy

There are currently no studies available

Surgical Study

There are currently no studies available

Radiotherapy Study

There are currently no studies available

Metastatic Disease: First-Line-Therapy

Title: A Phase 2, Randomized, Open-Label Study of Nivolumab Combined with Ipilimumab Versus Sunitinib Monotherapy in Subjects with Previously Untreated and Advanced (unresectable or metastatic) non-clear Cell Renal Cell Carcinoma
Phase: II
Contact: Margit Peters-Hornig / (Kontaktperson)
Email-Address: Margit.Peters-Hornig@med.uni-heidelberg.de
Clinical Investigator: Dr. Stefanie Zschäbitz
Registration: Die Studie ist bei den U.S. National Institutes of Health(ClinicalTrials.gov) registriert. Siehe NCT03075423
EudraCT-Number: siehe EU klinisches Studienregister 2016-000706-12
Title: A phase II single arm clinical trial of a Tailored ImmunoTherapy Approach with Nivolumab in subjects with metastatic or advanced Transitional Cell Carcinoma
Phase: II
Contact: Ulrike Lauterbach / (Study Nurse)
Email-Address: Ulrike.Lauterbach@med.uni-heidelberg.de
Clinical Investigator: Dr. Stefanie Zschäbitz
Registration: Keine Registernummer angegeben.
EudraCT-Number: siehe EU klinisches Studienregister 2016-004857-33

Metastatic Disease: Follow-Up Care

There are currently no studies available

Others

There are currently no studies available